Daewoong To Acquire China's Liaoning Baifeng For $16 Million
This article was originally published in PharmAsia News
Executive Summary
Daewoong Pharma said it would acquire China's Liaoning Baifeng for $16 million in an agreement between the two companies, with the South Korea buyer to build a drug-production plant in China by the end of 2017.